Media.Player

Preparation of Imidazole Pyrimidine Analogues as NEK2 Inhibitors for the Treatment of Cancer

Detailed Technology Description

Title: Preparation of Imidazole Pyrimidine Analogues as NEK2 Inhibitors for the Treatment of Cancer Invention: The invention is new kinds of imidazole pyrimidine analogues that inhibit NEK2 protein kinase and their use in cancer treatment. Initial results have demonstrated their efficacy in inhibiting proliferation of brain tumor stem cells and pancreatic cell lines. Background: The protein kinase NEK2 plays an essential role in the regulation of cell division. NEK2 is frequently over-expressed in a wide variety of cancers, where it is associated with tumorigenesis, tumor progression and contributes to drug resistance. NEK2 is therefore a promising therapeutic target for cancer treatment and great efforts have been made to develop NEK2 inhibitors. However, NEK2 inhibitors are still at an early stage of development, and up to now, no NEK2 inhibitor has been reported to undergo clinical trial. Applications:Cancer treatmentTreatment of chemo-resistant cancers like advanced resistant pancreas cancerPotential for combination therapy Advantages:A small molecule synthesized by common chemistry First-in-class NEK2 inhibitorsCancer cells that are resistant to other chemotherapy are sensitive to NEK2 inhibitionInhibits cell proliferation of cancer cells Licensing Manager:Rakhi GibbonsRakhiG@tla.arizona.edu(520) 626-6695

*Abstract

None

*Principal Investigator

Name: Hong yu Li, Associate Professor

Department: Pharmacology and Toxicology

Name: Brendan Frett, Postdoctoral Research Associate I

Department: Pharmacology and Toxicology

Name: Wenhao Hu, Professor

Department: Chemistry

Name: Ichiro Nakano

Department:

Name: Haiyong Han, Associate Investigator

Department:

Country/Region

USA